Only logged in users can watch the content

Chat keyboard_arrow_down
Description keyboard_arrow_down

Despite the numerous cancer therapies nowadays available in the market, cancer research is advancing from highly cytotoxic traditional therapies to a more personalized medicine by exploring and using precision oncology in order to precisely target the tumor cells and to reduce toxicity in the surrounding healthy tissues.

Moreover, several mechanisms to assess tumor progression and treatment response, such as predictive and progression biomarkers, have become imperative when it comes to keeping a precise cancer management and treatment decisions guidance. On that front, the tumor genetic profiling unveils details about its biology, especially when performing advanced molecular sequencing assays like multi-omics, generating big data that is accurately qualified and analyzed using bioinformatics and artificial intelligence (AI). 

Novel cancer targets and biomarkers are not the only discovered molecules with this process, but also new drugs are in silico designed and optimized with the use of AI, which certainly plays a key role in the drug discovery space. Enjoy this video where Dr. Joana Utrera provides us with an overview about the use of AI in precisiononcology and how advanced science and data analytics are paving the way for personalized medicine.
Faculty keyboard_arrow_down
Dr. Joana Utrera PhD in Molecular Biology at University of Barcelona. Master in Business Administration at EAE Business School, Project Manager at UC Berkeley, California. Digital Health Transformation
Related Content keyboard_arrow_down